Abstract 1720P
Background
On February 6, 2023, an earthquake occurred in Turkey that affected 11 provinces, many hospitals and millions of people. In Hatay, one of the provinces most affected by the earthquake, all 4 oncology centers in were partially or completely destroyed. So, a new unit was established in Dörtyol District Hospital, one of the few standing hospitals. On February 27, 2023, the first oncologist was assigned to the new oncology unit in Dörtyol Hospital. On 01 March 2023, the oncology outpatient clinic started to work and with the arrival of drugs, the first intravenous systemic anticancer treatment was administered on 03 March 2023. The aim of this abstract is to share our experience on how oncology services continue in the event of a major disaster.
Methods
In this abstract, the attempts made to provide oncology services after the earthquake in Hatay and the results of the first 100 patients followed in the new facility are summarized. The patients followed at the oncology outpatient clinic had their age, gender, primary diagnosis, and causes for admission retrospectively analysed.
Results
Between 01 and 10 March 2023, 100 patients applied to the oncology unit. A total of 62 of the patients were women. The median age of the group was 54. The most common diagnosis was breast cancer (N=46), followed by GIS (N=17) and lung (N=14) malignancies. The numbers of local, locoregional and metastatic diseases were 20, 33 and 47, respectively. Most common admission purpose was routine follow up (N=38), followed by scheduled systemic therapy (N=34). A total of 38 patients received systemic therapy while 9 had hormonotherapy and 3 had palliative treatment. Respectively, 5 patients were referred to different cities for PET scan, 3 patients for radiotherapy, and 7 patients due to the absence of drugs in the hospital.
Conclusions
Oncology is not a suitable field to delay or cancel active or palliative treatments. For this reason, it is inevitable to continue oncological services under all conditions, as has been seen in the recent COVID pandemic. On the other hand, due to the treatments applied, oncology centers have to meet some basic requirements in terms of infrastructure and work force. As in the Hatay experience, it is vital to take quick actions and ensure coordination after a disaster.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23